We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
From May 2019 to May 2024
By Kimberly Chin
Alexion Pharmaceuticals Inc. (ALXN) said it has named Aradhana Sarin as its next chief financial officer, succeeding CFO Paul Clancy later this year.
Ms. Sarin is currently Alexion's chief strategy and business officer. She joined the company in November 2017.
The transition will take place after the company reports its third-quarter financial results, Alexion said.
Mr. Clancy will assist Ms. Sarin with the transition, Alexion said. Mr. Clancy is expected to stay on as a senior adviser until mid-2020.
"I believe Alexion has great potential and the ability to achieve its strategic vision, and I will work with the entire team to ensure a seamless transition," Mr. Clancy said in prepared remarks.
Shares slipped 1.7% in after-hours trading to $106.01.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
September 17, 2019 16:45 ET (20:45 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
